Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.

@article{Yang2015MechanismsOP,
  title={Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.},
  author={Zhiyong Yang and Jeremy Ramsey and Therwa Hamza and Yongrong Zhang and Shan Li and Harris G. Yfantis and Dong Ho Lee and Lorraine D Hernandez and Wolfgang Seghezzi and Jamie M Furneisen and Nicole M Davis and Alex G. Therien and Hanping Feng},
  journal={Infection and immunity},
  year={2015},
  volume={83 2},
  pages={822-31}
}
Clostridium difficile infection (CDI) represents the most prevalent cause of antibiotic-associated gastrointestinal infections in health care facilities in the developed world. Disease symptoms are caused by the two homologous exotoxins, TcdA and TcdB. Standard therapy for CDI involves administration of antibiotics that are associated with a high rate of disease recurrence, highlighting the need for novel treatment paradigms that target the toxins rather than the organism itself. A combination… CONTINUE READING